Figure 1From: Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases Flow Chart of patient selection to collect all patients in one centre treated with either DMARDs or biologics for a rheumatic disease, and with concomitant bronchiectasis, with a follow-up of at least 3 months in our centre.Back to article page